Echo Therapeutics (OTCBB: ECTE) $2.00. Today announced that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Wednesday, January 20, 2010 at 9:42 AM ET and Friday January 22, 2010 at 10:24 AM ET. Dr. Mooney also will be a regular on-air guest on American Scene twice weekly and will be interviewed by host Steve Crowley regarding relevant corporate events, news releases and updates.
Steve Crowley's American Scene National Radio, owned by the Money Channel Inc., airs for three hours daily Monday through Friday. Money Channel also produces a national weekly television program, WallStreetCast, which airs on the FOX Business Network during certain times of the year. American Scene was launched nationally in June 1990, and WallStreetCast has been produced since 2005. Both programs feature personal finance advice, stock market-related news and advice, and they include regular CEO interviews of Micro-cap and Small-cap companies. American Scene has over 3,000,000 listeners on the three-hour daily radio broadcasts and airs on hundreds of radio channels nation-wide through the IRN/USA Radio Network affiliates.
"We are extremely excited to be interviewed by Steve Crowley, a Wall Street legend, on his American Scene radio program," commented Dr. Mooney. "Echo Therapeutics recently completed the initial product development work on our Prelude SkinPrep System and we are now focused on completing steps for our regulatory advance to commercialization and leveraging our strategic partnerships to generate product-related revenue. We believe the investors who listen to these shows will be interested in our story because we are positioned to be 'first-to-market' with a proven, needleless, transdermal continuous glucose monitoring system in the $1 billion-plus hospital critical care market. In addition, we anticipate near-term revenue for Echo from the royalties on Prelude disposables and lidocaine sales, and we look forward to working with Ferndale Pharma Group to generate cash flow to Echo from the topical anesthetic market in the US and UK during 2010. Finally, we are targeting an application to secure a national exchange listing in the near future, further increasing our visibility to investors and expanding our audience of potential investors. With these important milestones in view, we believe we have reached a compelling point in Echo's history, so the timing couldn't be better for us to share our story with the American Scene and WallStreetCast audiences."
What They Do: Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.
Netlist, Inc. (Nasdaq: NLST) $4.67, Today announced that the United States Patent and Trademark Office issued to Netlist Patent No. 7,636,274 for its invention related to memory load isolation and memory rank multiplication, and Patent No. 7,619,912 for its invention related to memory rank multiplication. These fundamental technologies are integral to Netlist's Hypercloud product line which maximizes server utilization by removing memory capacity and bandwidth bottlenecks, thereby improving datacenter performance.
"The issuance of the '912 and '274 patents further reinforces the innovations Netlist is delivering to the market with highly differentiated products," said C.K. Hong, President and CEO of Netlist. "These are foundational patents and with our robust portfolio of intellectual property, we can uniquely address the system challenges our customers face in the datacenter."
What They Do: Netlist designs, manufactures and sells high-performance memory subsystems for the server, storage, and high- performance computing and communications markets.
OSI Systems (Nasdaq: OSIS) $30.69. Today announced that its Security division, Rapiscan Systems, has been awarded an approximate $35 million contract from Grupo Aeroportuario del Pacifico (GAP) for a turn-key aviation security project for the construction and installation of baggage handling systems integrated with the Rapiscan MVXR5000 high-speed multi-view X-ray hold baggage screening systems at multiple Mexican airports.
GAP operates 12 airports throughout Central and Northern Mexico including the major cities of Guadalajara and Tijuana and tourist destinations such as Puerto Vallarta, Los Cabos, La Paz and Manzanillo.
What They Do: OSI Systems, Inc. is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications in the homeland security, healthcare, defense and aerospace industries.
RXi Pharmaceuticals Corporation (Nasdaq: RXII) $5.55. Today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia’s RNA Silencing: Mechanism, Biology and Application held January 14-19 in Keystone, Colorado.
“RXi has progressed substantially in advancing its technology and building a robust and differentiated RNAi therapeutic platform. Our cutting-edge innovation has led to the discovery and development of novel RNAi compounds with improved drug-like properties that may enable the development of therapeutics for a wide range of indications. By having such a broad platform, we believe that we are well positioned to focus on the most promising therapeutic areas and to select the right candidates to take forward into development,” commented Anastasia Khvorova, Ph.D., RXi’s Chief Scientific Officer.
What They Do: RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has been compensated three thousand five hundred dollars by a third party Green Horseshoe for its services with regards to Echo Therapeutics. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
